E.g., 12/08/2019
E.g., 12/08/2019
Title Category Credit Event date Price
Adjuvant Therapy in RCC Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Annual Meeting Highlights (2019): Genitourinary Cancer
    • 1.25 AMA PRA Category 1 Credit™
    • 1.25 Non-Physician Participation
$0.00 To better meet the educational needs of urologists and advanced practice providers (APPs), in 2017 the AUA gathered data from a variety of sources, including a comprehensive literature search, as well as membership surveys to determine where gaps exist in knowledge, proficiency, and practice in regards to genitourinary (GU) cancer.
AUA2017 OnDemand Course Pass (2017) $299.00 Access some of the latest science from AUA2017 through the On-Demand Course Pass! The On-Demand Course Pass provides access to Webcasts of more than 90 instructional courses presented at AUA2017. Course topics span the spectrum of urologic medicine.
AUA2018 Abstracts and Posters (2018) $0.00 Member only benefit! This is a collection of abstracts presented at the AUA2018.This product does not provide CME.To access abstracts and posters, click REGISTER/TAKE COURSE tab. Then click ENROLL at the bottom of the page.
AUA2018 San Francisco Virtual Meeting (2018) $699.00 NEW for 2018: AUA2018 Virtual Meeting - Members Save $100!Access the latest science from the 2018 AUA Annual Meeting with the AUA2018 VIRTUAL MEETING.The Virtual Meeting provides online access to hundreds of scientific presentations from AUA2018, including:
Chemo-ablation of Upper-Tract Urothelial Carcinoma Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Clinical Investigations in the Treatment of Urothelial Carcinoma Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Complex Patient Cases in Bladder Cancer Webcast (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
CPS Muscle Invasive Bladder Cancer (2017)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of muscle invasive bladder cancer (MIBC).
CPS Non-Muscle Invasive Bladder Cancer (2016)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. This guideline provides a risk-stratified clinical framework for the management of NMIBC.
Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Highlights in the Medical Management of Urothelial Carcinoma: Advanced and Metastatic Urothelial Carcinoma (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma (see below for a link to the activity)2) Management of Advanced and Metastatic Urothelial Carcinoma
Highlights in the Medical Management of Urothelial Carcinoma: Non-Muscle Invasive Urothelial Carcinoma (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma 2) Management of Advanced and Metastatic Urothelial Carcinoma (see below for a link to the activity)
Immune Checkpoint Inhibitors in RCC Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Immunotherapy: From Research to Practice Webcast (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.

Pages